Expression and prognostic significance of bcl-2 apoptosis inhibitor in renal cell carcinoma


Cite item

Full Text

Abstract

This articlepresents the study of prognostic significance of bcl-2 apoptosis inhibitor expression in renal cell carcinoma. Operation samples of 59 patients with renal cell carcinoma were studied. Average age of patients was 56,6 ± 1,3 years. 31 (52,5 %) were men , 28 (47,5 %)-women . Correlations were found between bcl-2, clinical cancer stage (r = 0,31; р = 0,02), size of tumor node (r = 0,29; р = 0,02), regional and distant metastasis ( r = 0,35; р = 0,005) and histologic tumor type (r = 0,41; р = 0,002). No correlation was found with patients ’ sex (r = 0,16; р = 0,22), age (r = 0,17; р = 0,22) and tumor grade by Furman (r = 0,19; р = 0,15). Absence of bcl- 2 expression in tumor cells can be considered as a marker of possible metastases. The results showed correlation between the marker expression and overallsurvival was. Low level of bcl-2 oncoprotein expression in tumor cells is apoorprognostic factor of fatient’s survival.

About the authors

Tat’yana M. Cherdantseva

The Altai State Medical University

Email: drakon@agmu.ru
MD, PhD 656038, Barnaul, Russian Federation

I. P Bobrov

The Altai State Medical University

656038, Barnaul, Russian Federation

A. F Lazarev

N.N. Blokhin Russian Cancer Research Center

The Altai Branch 656049, Barnaul, Russian Federation

V. V Klimachev

The Altai State Medical University

656038, Barnaul, Russian Federation

A. M Avdalyan

The Altai State Medical University

656038, Barnaul, Russian Federation

References

  1. Uchida T., Gao J.P., Wang C., Jiang S.X., Muramoto M., Satoh T. et al. Clinical significance of p53, mdm2, and bcl-2 proteins in renal cell carcinoma. Urology. 2002; 59: 615-20.
  2. Gobe G., Rubin M., Williams G., Sawczuk I., Buttyan R. Apoptosis and Expression of Bcl-2, Bcl-XL, and Bax in renal cell carcinomas. Cancer Invest. 2002; 20: 324-32.
  3. Huang A., Fone P.D., Gandour-Edwards R., White R.W., Low R.K. Immunohistochemical analysis of Bcl-2 protein expression in renal cell carcinoma. J. Urol. 1999; 162: 610-3.
  4. Zhang X., Takenaka I. Cell proliferation and apoptosis with BCL-2 expression in renal cell carcinoma. Urology. 2000; 56: 510-1.
  5. Гуторов С.Л., Степанова Е.В., Вишневская Я.В., Черноглазова Е.В., Соколова И.Н., Матвеев В.Б. Прогностическое значение экспрессии тимидинфосфорилазы, Bcl-2 и Ki-67 при раке почки H-2N0M0. Онкоурология. 2007; 4: 21-5.
  6. Hinderman W., Berndt A., Wunderlich H. et al. Quntitative evaluation of apoptosis and proliferation in renal cell carcinoma. Correlation to tumor subtype, cytological grade according to thoenes - classification and occurrence of metastasis. Pathol. Res. Pract. 1997; 193: 1-7.
  7. Itoi Y, Bilim V, Takahashi K., Tomita F. Impact of frequent Bcl-2 expression on better prognosis in renal cell carcinoma patients. Br. J. Cancer. 2004; 90: 200-5.
  8. Vasavada S.P., Novick A.C., Williams B.R. p53, bcl - 2, and Bax expresion in renal cell carcinoma. Urology. 1998; 51: 1057-61.
  9. Oudard S., Levalois C., Andrieu J.M., Bougaran J., Validire P., Thiounn N. et al. Expression of genes involved in chemoresistance, proliferation and apoptosis in clinical samples of renal cell carcinoma and correlation with clinical outcome. Anticancer Res. 2002; 22: 121-8.
  10. Sanchez Tejido A., Sanchez Chapado M., Duarte Ojeda J.M., Tamayo Ruiz J.C., Ruiz Ramos P., Ruiz Villaespesa A., Leiva Galvis O. Apoptosis in renal adenocarcinoma. Expression of bcl-2 in locally confined tumors. Actas Urol Esp. 2002; 26: 41-5.
  11. Selma T., Miyagawa I. Significance of Fas expression alteration during tumor progression of renal cell carcinoma. Int. J. Urol. 2006; 13: 257-64.
  12. Paraf F., Gogusev J., Chretien Y, Droz D. Expression of bcl-2 oncoprotein in renal cell tumours. J. Pathol. 1995; 177(3): 247-52.
  13. Skolarikos A., Alivizatos G., Bamias A., Mitropoulos D., Ferakis N., Deliveliotis C., Dimopoulos M.A. Bcl-2 protein and DNA ploidy in renal cell carcinoma: do they affect patient prognosis? Int. J. Urol. 2005; 12: 563-9.
  14. Kanamaru H., Li B., Miwa Y., Akino H., Okada K. Immunohistochemical expression of p53 and bcl-2 proteins is not associated with sarcomatoid change in renal cell carcinoma. Urol. Res. 1999; 27: 169-73.
  15. Лоран О.Б., Франк Г.А., Серегин А.В., Завалишина Л.Э., Андреева Ю.Ю., Серегин А.А., Шустицкий Н.А. Факторы апоптоза и пролиферации при раке почки. Онкоурология. 2008; 2: 16-21.
  16. Шустицкий Н.А. Факторы апоптоза и пролиферации в течении рака почки: Дис.. канд. мед. наук. М.; 2007.
  17. Pammer J., Exner M., Regele H., Haitel A., Weninger W., Horvat R., Susani M. Expression of bcl-2, bcl-x, bax and bak in renal parenchyma, oncocytomas and renal cell carcinomas. Pathol. Res. Pract. 1998; 194: 837-45.
  18. Kallio J.P., Hirvikoski P., Luukkaala T., Tammela T.L., Kellokumpu-Lehtinen P., Martikainen P.M. Renal cell carcinoma MIB-1, Bax and Bcl-2 expression and prognosis. J. Urol. 2004; 172: 2158-61.
  19. Fuhrman S.A., Lasky L.C., Limas C. Prognostic significance of morfologic parameters in renal cell carcinoma. Am. J. Surg. Pathol. 1982; 6: 655-63.

Copyright (c) 2015 Eco-Vector


 


This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies